Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 MT-0551 (inebilizumab) in systemic sclerosis
jRCT2031210521Phase 3Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing MT-0551 (inebilizumab) group with Placebo group (2 arms). Primary endpoint: Change from baseline in the mRTSS up to the end of the long-term extension period. Started Jul 2022; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2031210521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210521.